E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies.
TL;DR: The various modalities used for CNS prophylaxis in patients with ALL and the emerging trends are discussed, with specific emphasis on the outcome in terms of event‐free survival and toxicity.
Journal ArticleDOI
Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.
Jorge E. Cortes,Hagop M. Kantarjian,Tapan M. Kadia,Gautam Borthakur,Marina Konopleva,Guillermo Garcia-Manero,Naval Daver,Naveen Pemmaraju,Elias Jabbour,Zeev Estrov,Abhijit Ramachandran,Jamil Paradela,Blake Pond,Farhad Ravandi,Madhuri Vusirikala,Prapti A. Patel,Mark J. Levis,Alexander E. Perl,Michael Andreeff,Robert H. Collins +19 more
TL;DR: Investigating the clinical activity, PK, safety and resistance mechanisms to single-agent crenolanib patients with refractory/relapsed acute myeloid leukemia with FLT3 ITD found Pts < 60 had a higher survival than those ≥ 60 (OS 185d).
Journal ArticleDOI
Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.
Dushyant Verma,Hagop M. Kantarjian,Sara S. Strom,Mary Beth Rios,Elias Jabbour,Alfonso Quintás-Cardama,Srdan Verstovsek,Farhad Ravandi,Susan O'Brien,Jorge E. Cortes +9 more
TL;DR: No evidence at the moment suggests that exposure to TKIs increases the risk of developing second cancers, and second cancers occur in a small percentage of patients receiving therapy with TKI for hematologic malignancies, mostly CML.
Journal ArticleDOI
Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3 internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Ali Bazarbachi,Gesine Bug,Frédéric Baron,Eolia Brissot,Fabio Ciceri,Iman Abou Dalle,Hartmut Döhner,Jordi Esteve,Yngvar Fløisand,Sebastian Giebel,Maria H. Gilleece,Norbert Claude Gorin,Elias Jabbour,Mahmoud Aljurf,Hagop M. Kantarjian,Mohamed A. Kharfan-Dabaja,Myriam Labopin,Francesco Lanza,Florent Malard,Zinaida Peric,Thomas Prebet,Farhad Ravandi,Annalisa Ruggeri,Jaime Sanz,Christoph Schmid,Roni Shouval,Alexandros Spyridonidis,Jurjen Versluis,Norbert Vey,Bipin N. Savani,Arnon Nagler,Mohamad Mohty +31 more
TL;DR: A position statement is developed on best approaches for allogeneic hematopoietic SCT for AML with FLT3-internal tandem duplication including indications for and modalities of such transplants and on the potential optimization of post-transplant maintenance withFLT inhibitors.
Journal ArticleDOI
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial
Nicholas J. Short,Hagop M. Kantarjian,Sanam Loghavi,Xuelin Huang,Wei Qiao,Gautam Borthakur,Tapan M. Kadia,Naval Daver,Maro Ohanian,Courtney D. DiNardo,Zeev Estrov,Rashmi Kanagal-Shamanna,Abhishek Maiti,Christopher B. Benton,Prithviraj Bose,Yesid Alvarado,Elias Jabbour,Steven M. Kornblau,Naveen Pemmaraju,Nitin Jain,Yvonne Gasior,Mary Ann Richie,Sherry Pierce,Jorge E. Cortes,Marina Konopleva,Guillermo Garcia-Manero,Farhad Ravandi +26 more
TL;DR: In older patients with newly diagnosed acute myeloid leukaemia, efficacy and safety did not differ by the 5-day or the 10-day decitabine schedule, and overall survivaldid not differ between groups when stratified by cytogenetics, de-novo versus secondary or therapy-related acute myELoid leukemia, or TP53mut status.